Study Finds Benefits to Second Peritoneal Mesothelioma SurgeryResearch & Clinical Trials
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Povtak, T. (2022, July 13). Study Finds Benefits to Second Peritoneal Mesothelioma Surgery. Asbestos.com. Retrieved January 28, 2023, from https://www.asbestos.com/news/2022/04/13/benefits-peritoneal-mesothelioma-surgery/
Povtak, Tim. "Study Finds Benefits to Second Peritoneal Mesothelioma Surgery." Asbestos.com, 13 Jul 2022, https://www.asbestos.com/news/2022/04/13/benefits-peritoneal-mesothelioma-surgery/.
Povtak, Tim. "Study Finds Benefits to Second Peritoneal Mesothelioma Surgery." Asbestos.com. Last modified July 13, 2022. https://www.asbestos.com/news/2022/04/13/benefits-peritoneal-mesothelioma-surgery/.
Patients with peritoneal mesothelioma cancer can survive considerably longer if they are willing and able to undergo a second aggressive surgery following tumor recurrence.
History has proven that an incentive for a repeat surgery is there.
A recent 30-year retrospective review at Wake Forest Baptist Medical Center has shown how beneficial the combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, or HIPEC, can be for several cancers with peritoneal metastasis.
“People often think it’s a one-and-done procedure,” Wake Forest Baptist surgical oncologist Dr. Edward Levine told The Mesothelioma Center at Asbestos.com. “But it’s not always that way. For some, a repeat surgery can be a real life-extending event.”
Annals of Surgical Oncology published the review in March. It was co-authored by members of Wake Forest’s surgical oncology and biostatistics and data science departments.
Wake Forest Baptist Medical Center is one of the world’s most acclaimed facilities for the treatment of peritoneal malignancies. It was among the first to establish a HIPEC program, in 1991.
Mesothelioma Surgery with HIPEC Extends Survival
Cytoreductive surgery is an aggressive and lengthy procedure designed to remove all visible tumor cells from the abdomen. It can include removing parts or all of the gallbladder, liver, pancreas, spleen and intestinal tract.
HIPEC, used immediately after the surgery, involves circulating heated chemotherapy throughout the abdominal cavity in hopes of killing any microscopic tumor cells left behind by the surgeon.
The recent single-center study involved 156 patients from 1991-2021 who received the cytoreductive surgery and HIPEC combination at least twice.
During that period, 1,547 patients were treated with the combination at least once for a peritoneal malignancy, mostly for appendix, colorectal or mesothelioma cancers.
Of the 156 repeat-surgery patients, 17 had peritoneal mesothelioma. Appendix cancer dominated the repeat-surgery group with 102.
The 156 patients who received the combination multiple times had a median survival of 10.7 years, compared to just 2.5 years for those having it only once. Seventeen patients underwent the procedure three times and one patient was treated with it four times.
Peritoneal mesothelioma patients receiving the treatment at least twice had a median survival of 67.7 months, more than double the estimated median survival for patients receiving it only once.
The mesothelioma patients in the review also had a median survival of 32.2 months after the second surgery, compared to 40.1 months for those with colorectal cancer.
Surgery Remains Best Treatment for Recurrence
“Historically, I think this has shown if there is a recurrence, another surgery is still the best treatment when it comes to survival,” Dr. Perry Shen, a Wake Forest Baptist surgical oncologist and study co-author, told The Mesothelioma Center. “Tolerating multiple major operations can be done – with the right patients.”
Peritoneal mesothelioma is a rare cancer most often caused by an exposure to asbestos and diagnosed in fewer than 500 people annually in the U.S. Both Levine and Shen emphasized the importance of patients being treated at a specialty center with considerable experience in selecting patients for surgery.
Although the combination of cytoreductive surgery and HIPEC is considered the most effective treatment for mesothelioma, fewer than half of those diagnosed receive it. Most oncologists rarely see the disease and treat it only with standard chemotherapy, leading to an average survival of less than one year.
Peritoneal Mesothelioma Surgery Underutilized
One recent study, conducted by researchers at Inova Fairfax Medical Campus in Virginia, found that a large percentage of patients who could have been helped by cytoreductive surgery and HIPEC – and had their survival extended significantly – were not having the surgery for various reasons.
Although some patients are denied surgery because of age, overall health reasons or disease progression, those are not the majority with peritoneal mesothelioma.
One reason for the lack of surgery is its association with the tougher-to-treat and more prevalent pleural mesothelioma, which develops in the thoracic cavity and has a much shorter survival time.
Only an estimated one-fourth of the patients with pleural mesothelioma even qualify for aggressive surgery.
This most recent review at Wake Forest also showed little difference in complication rates between the first surgery and second, for both the overall group and the peritoneal mesothelioma group.
For the 17 mesothelioma patients undergoing repeat surgery, only two had serious complications after the first surgery and just three had complications after the second surgery.
“When you looked at the data, it was a pleasant surprise. The complication rates were comparable,” Shen said. “Part of that is, we’re selecting patients who we think can do well with it. It’s another reason patients should go to a high-volume center with experience. The procedure can extend survival.”